Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
- Conditions
- Metastatic Renal Cell Cancer
- Registration Number
- NCT00655252
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This expanded access study is designed to provide RAD001 to patients with MRCC who are without satisfactory treatment alternatives, until RAD001 becomes commercially available.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (40)
Highlands oncology Group, PA
🇺🇸Springdale, Arkansas, United States
University of Colorado Health Sciences Center/Anschutz Pavillion
🇺🇸Aurora, Colorado, United States
Cancer Centers of Florida, P.A.
🇺🇸Ocoee, Florida, United States
MD Anderson Cancer Center - Orlando
🇺🇸Orlando, Florida, United States
Indiana University Cancer center
🇺🇸Indianapolis, Indiana, United States
The Cancer Institute, St. Joseph Medical Center
🇺🇸Towson, Maryland, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Missouri Cancer Associates
🇺🇸Columbia, Missouri, United States
Heartland Hematology-Oncology Associates, Inc.
🇺🇸Kansas City, Missouri, United States
Washington University/Siteman Cancer Center
🇺🇸St. Louis, Missouri, United States
Scroll for more (30 remaining)Highlands oncology Group, PA🇺🇸Springdale, Arkansas, United States